Ignite Creation Date:
2025-12-24 @ 11:24 PM
Ignite Modification Date:
2026-01-02 @ 5:58 PM
Study NCT ID:
NCT05384756
Status:
RECRUITING
Last Update Posted:
2024-12-31
First Post:
2022-05-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Sponsor:
City of Hope Medical Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
20682
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | NIH | View |